Show simple item record

dc.contributor.authorHuis In 't Veld, EAen_US
dc.contributor.authorGrünhagen, DJen_US
dc.contributor.authorDeroose, JPen_US
dc.contributor.authorNijsten, TECen_US
dc.contributor.authorWouters, MWJMen_US
dc.contributor.authorVerhoef, Cen_US
dc.contributor.authorvan Houdt, WJen_US
dc.contributor.authorHayes, AJen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2018-11-30T09:09:49Z
dc.date.issued2018-08en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/29961756en_US
dc.identifier10.1038/s41416-018-0149-zen_US
dc.identifier.citationBr J Cancer, 2018, 119 (4), pp. 429 - 434en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2964
dc.identifier.eissn1532-1827en_US
dc.identifier.doi10.1038/s41416-018-0149-zen_US
dc.description.abstractBACKGROUND: A small minority of patients present with locally advanced cutaneous Squamous Cell Carcinoma (cSCC). The aim of this study was to evaluate the effectiveness of Tumour necrosis factor α (TNF) and melphalan based isolated limb perfusion (TM-ILP) as a limb saving strategy for locally advanced extremity cSCC. METHODS: A retrospective search from prospectively maintained databases, at two tertiary referral centers, was performed to identify patients treated with TM-ILP for locally advanced cSSC of an extremity between 2000 and 2015. RESULTS: A total of 30 patients treated with TM-ILP for cSCC were identified, with a median age of 71 years (36-92) and 50% female. Response could not be evaluated in 3 patients. After a median follow up of 25 months, the overall response rate was 81% (n = 22), with 16 patients having a complete response (CR, 59%). A total of 7 patients developed local recurrence, with a median time to recurrence of 9 months (Interquartile Range 7-10). Progressive disease was observed in 5 patients (19%). Limb salvage rate was 80%. The overall 2-year survival was 67%. CONCLUSIONS: TM-ILP should be considered as an option in patients with locally advanced cSCC in specialised centers, resulting in a high limb salvage rate.en_US
dc.format.extent429 - 434en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden_US
dc.titleIsolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy.en_US
dc.typeJournal Article
dcterms.dateAccepted2018-05-22en_US
rioxxterms.versionofrecord10.1038/s41416-018-0149-zen_US
rioxxterms.licenseref.startdate2018-08en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBr J Canceren_US
pubs.issue4en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Sarcoma and Melanoma Surgery
pubs.publication-statusPublisheden_US
pubs.volume119en_US
pubs.embargo.termsNot knownen_US
icr.researchteamSarcoma and Melanoma Surgeryen_US
dc.contributor.icrauthorHayes, Andrewen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record